Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brian Lian
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 65
- Beta
- 0.69
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 14.71
Financials
Net Income
$-128.02MEBITDA
$-127.86MFree Cash Flow
$-125.17MEPS (diluted)
$-1.10Shares Outstanding (diluted)
115.92M+510.3%Operating Expenses
$132.60MCash & Debt
$501.66MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-359.64M | $-3.19 |
| 2024 | $0.00 | $-109.96M | $-1.01 |
| 2023 | $0.00 | $-85.89M | $-0.91 |
| 2022 | $0.00 | $-68.87M | $-0.88 |
| 2021 | $0.00 | $-54.99M | $-0.70 |
| 2020 | $0.00 | $-39.49M | $-0.50 |
| 2019 | $0.00 | $-25.78M | $-0.36 |
| 2018 | $0.00 | $-22.06M | $-0.38 |
| 2017 | $0.00 | $-20.58M | $-0.79 |
| 2016 | $0.00 | $-14.73M | $-0.90 |
| 2015 | $0.00 | $-23.40M | $-3.68 |
| 2014 | $0.00 | $-21.88M | $-5.08 |
| 2013 | $0.00 | $-146.2K | $-0.03 |
| 2012 | $0.00 | $-444.11 | $-0.30 |
Valuation
VKTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (2)
- Newsprnewswire.com·5h ago·Neutral
Viking Therapeutics to Participate at Upcoming Investor Conferences SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in September.
View source ↗ - Newsfool.com·3d ago·Negative
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next. The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.
View source ↗
Earnings
Wed, Oct 28(in 8 weeks)
Consensus estimate $-1.07 per share
Typical surprise -20.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-1.10 vs $-1.23beat
- Wed, Apr 29$-1.37 vs $-1.01miss
- Wed, Feb 11$-1.38 vs $-0.89miss
- Wed, Oct 22$-0.81 vs $-0.70miss
- Wed, Jul 23$-0.58 vs $-0.44miss
- Wed, Apr 23$-0.41 vs $-0.34miss
Estimates and results for VKTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VKTX officers and directors.
- Bought
- $180k
- Sold
- $42.0m
2 trades
33 trades
- Lian Briansold
- Zante Gregsold
- Mancini Mariannasold
- Aubuchon Neil Williambought
- Zante Gregsold
- Zante Gregsold
- Zante Gregsold
- Zante Gregsold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.